Experimental and Investigational Treatment Appeals

Being denied coverage because a treatment is labeled "experimental" or "investigational" is one of the most frustrating denials to receive — especially when your physician believes the treatment offers your best chance for recovery. The good news is that this denial type is frequently successfully appealed, particularly when you understand the legal standards and know how to counter the insurer's characterization.

How Insurers Define "Experimental"

Most health plans define experimental or investigational treatment as a service that: is not recognized as standard medical practice; is not supported by sufficient clinical evidence from well-controlled studies; does not have approval from the relevant regulatory authority (e.g., FDA) for the specific indication; or is being provided as part of a clinical trial where the primary purpose is to evaluate safety or effectiveness.

The critical word is "sufficient." Insurers often apply an outdated or overly narrow definition of clinical evidence, ignoring substantial peer-reviewed literature that supports a treatment. Courts have consistently found that insurers cannot rely on outdated definitions when current clinical evidence clearly supports a treatment.

Strategy 1: Establish FDA Approval Status

FDA approval is the most powerful counter to an experimental denial. If your treatment has FDA clearance or approval, that directly contradicts the "experimental" characterization:

• FDA 510(k) clearance (medical devices): Establishes substantial equivalence to a legally marketed device
• FDA premarket approval (PMA): The most rigorous FDA device review; establishes safety and effectiveness
• FDA drug approval (NDA/BLA): Full approval for the specific indication
• FDA Breakthrough Therapy Designation: Indicates the FDA found the drug may offer substantial improvement over available therapy — this status argues strongly against an "experimental" characterization
• FDA Accelerated Approval: Approval based on surrogate endpoints reasonably likely to predict clinical benefit

Search the FDA database at accessdata.fda.gov to verify and document your treatment's approval status.

Strategy 2: Off-Label Use Protections

Approximately 20% of cancer drug prescriptions and significant portions of other specialty drug prescriptions are "off-label" — meaning the drug is FDA-approved but being used for an indication not listed on the label. Off-label use is common, legitimate, and supported by medical practice. Several specific protections apply:

• Cancer drug off-label protections: Most states require coverage of off-label cancer drug use when supported by recognized clinical drug compendia (USP DI Drug Information, AHFS Drug Information, DRUGDEX, Clinical Pharmacology, or National Cancer Institute publications). Many federal laws mandate this for certain cancer drugs under Medicare and Medicaid.
• NCCN Compendium: The National Comprehensive Cancer Network Compendium is specifically recognized by Medicare and many states as authoritative for cancer drug coverage determinations, even for off-label use.
• 42 U.S.C. §1395x(t)(2): Medicare must cover off-label anti-cancer drugs described in one of the approved compendia or supported by clinical evidence in peer-reviewed medical literature.

Strategy 3: Use Clinical Guidelines

Major specialty society guidelines that include a treatment provide strong evidence it is not experimental:

• NCCN Guidelines: For oncology, NCCN Category 1 or 2A recommendations carry maximum weight. Even Category 2B recommendations can support an appeal.
• ACC/AHA Guidelines: Class I or IIa cardiac treatment recommendations
• ACR Appropriateness Criteria: For imaging and interventions
• APA Practice Guidelines: For psychiatric treatments

When citing guidelines, include the specific category/class of recommendation and the evidence level. Guideline inclusion directly contradicts an insurer's "experimental" characterization.

Strategy 4: Challenge the Review Process

Under ERISA and ACA regulations, the clinician conducting the experimental/investigational determination must have relevant specialty expertise. An insurer cannot have a general internist make an "experimental" determination about a cutting-edge oncology treatment. Request:

• The credentials and specialty of the reviewing clinician
• The specific evidence review process used
• The date the clinical evidence was last reviewed (older reviews miss newer evidence)
• Whether the review accounted for the specific clinical guidelines you will be citing

When Treatment Is Genuinely Investigational

If your treatment is truly experimental and enrolled in a clinical trial, you may still have coverage rights. Under ACA §2709 (42 U.S.C. §300gg-8), non-grandfathered plans must cover routine patient costs for individuals participating in approved clinical trials for life-threatening or serious conditions. "Routine costs" include visits, lab work, and other care you would receive outside the trial. The experimental treatment itself may not be covered, but your regular care costs must be.

Sample Appeal Language

"The denial of [treatment] as 'experimental or investigational' is factually incorrect. [Treatment] received FDA approval/clearance on [date] for [indication]. Additionally, [treatment] is included in [NCCN/ACC/AHA] guidelines as a [Category X] recommendation for [condition]. The insurer's 'experimental' determination fails to reflect the current scientific and medical consensus, as evidenced by the attached peer-reviewed literature and clinical guidelines. The reviewing clinician's [specialty/credentials] may not be appropriate for determining the evidence base for this [specialty] treatment, and we request review by a specialist in [relevant specialty]."